Literature DB >> 17507833

A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women.

Jan L Shifren1, Sophie Desindes, Marilyn McIlwain, Gheorghe Doros, Norman A Mazer.   

Abstract

OBJECTIVE: To compare the changes induced by oral versus transdermal estrogen therapy on the total and free serum concentrations of testosterone (T), thyroxine (T4), and cortisol (C) and the concentrations of their serum binding globulins sex hormone-binding globulin, thyroxine-binding globulin, and cortisol-binding globulin in naturally menopausal women.
DESIGN: Randomized, open-label, crossover. Interventions included a 6-week withdrawal from previous hormone therapy (baseline), followed in randomized order by 12 weeks of oral conjugated equine estrogens (CEE) (0.625 mg/d) and 12 weeks of transdermal estradiol (TD E2) (0.05 mg/d), with oral micronized progesterone (100 mg/d) given continuously during both transdermal estrogen therapy regimens.
RESULTS: Twenty-seven women were enrolled in the study, and 25 completed both treatment periods. The mean(SD) percentage changes from baseline of sex hormone-binding globulin, total T, and free T with oral CEE were +132.1% (74.5%), +16.4% (43.8%), and -32.7% (25.9%), respectively, versus +12.0% (25.1%), +1.2% (43.7%), and +1.0% (45.0%) with TD E2. The mean (SD) percentage changes of thyroxine-binding globulin, total T4, and free T4 with oral CEE were +39.9% (20.1%), +28.4% (29.2%), and -10.4% (22.3%), respectively, versus +0.4% (11.1%), -0.7% (16.5%), and +0.2% (26.6%) with TD E2. The mean (SD) percentage changes of cortisol-binding globulin, total C, and free C with oral CEE were +18.0% (19.5%), +29.2% (46.3%), and +50.4% (126.5%), respectively, versus -2.2% (11.3%), -6.7% (30.8%), and +1.8% (77.1%) with TD E2. Concentrations of all hormones and binding globulins were significantly different (P < or = 0.003) during administration of oral versus transdermal estrogen therapy, except for free T4 and free C.
CONCLUSIONS: Compared with oral CEE, TD E2 exerts minimal effects on the total and free concentrations of T, T4, and C and their binding proteins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17507833     DOI: 10.1097/gme.0b013e31803867a

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  15 in total

1.  Testosterone and progesterone, but not estradiol, stimulate muscle protein synthesis in postmenopausal women.

Authors:  Gordon I Smith; Jun Yoshino; Dominic N Reeds; David Bradley; Rachel E Burrows; Henry D Heisey; Anna C Moseley; Bettina Mittendorfer
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

2.  Body composition and bone mineral density after ovarian hormone suppression with or without estradiol treatment.

Authors:  Karen L Shea; Kathleen M Gavin; Edward L Melanson; Ellie Gibbons; Anne Stavros; Pamela Wolfe; John M Kittelson; Sheryl F Vondracek; Robert S Schwartz; Margaret E Wierman; Wendy M Kohrt
Journal:  Menopause       Date:  2015-10       Impact factor: 2.953

3.  Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS).

Authors:  Hugh S Taylor; Aya Tal; Lubna Pal; Fangyong Li; Dennis M Black; Eliot A Brinton; Matthew J Budoff; Marcelle I Cedars; Wei Du; Howard N Hodis; Rogerio A Lobo; JoAnn E Manson; George R Merriam; Virginia M Miller; Frederick Naftolin; Genevieve Neal-Perry; Nanette F Santoro; Sherman M Harman
Journal:  JAMA Intern Med       Date:  2017-10-01       Impact factor: 21.873

4.  A case-control study of levothyroxine and the risk of colorectal cancer.

Authors:  Gad Rennert; Hedy S Rennert; Mila Pinchev; Stephen B Gruber
Journal:  J Natl Cancer Inst       Date:  2010-03-19       Impact factor: 13.506

5.  Longitudinal associations of the endocrine environment on fat partitioning in postmenopausal women.

Authors:  Amy M Goss; Betty E Darnell; Marian A Brown; Robert A Oster; Barbara A Gower
Journal:  Obesity (Silver Spring)       Date:  2011-12-15       Impact factor: 5.002

6.  Use of hormone replacement therapy and the risk of colorectal cancer.

Authors:  Gad Rennert; Hedy S Rennert; Mila Pinchev; Ofer Lavie; Stephen B Gruber
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

7.  Cortisol levels during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study.

Authors:  Nancy Fugate Woods; Ellen Sullivan Mitchell; Kathleen Smith-Dijulio
Journal:  Menopause       Date:  2009 Jul-Aug       Impact factor: 2.953

Review 8.  Androgen replacement therapy in androgen-deficient women with hypopituitarism.

Authors:  Hong Zang; Susan R Davis
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Effects of estrogen versus estrogen and progesterone on cortisol and interleukin-6.

Authors:  Kate M Edwards; Paul J Mills
Journal:  Maturitas       Date:  2008-11-17       Impact factor: 4.342

Review 10.  Sexual dimorphism in skeletal muscle protein turnover.

Authors:  Gordon I Smith; Bettina Mittendorfer
Journal:  J Appl Physiol (1985)       Date:  2015-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.